Researchers at the University of California, Davis have developed a unique method for site-specific ligation and conjugation of compounds to existing antibodies.
Traditionally, non-specific ligation methods have been used to chemically modify immunoglobulins. Through these methods, cytotoxic compounds are generally conjugated to antibodies via targeting of: (i) amines of lysine residues and (ii) free sulfhydryls of cysteine residues. These modifications, however, lead to heterogeneous products due to the multiple instances of identical functional groups. Therefore, there is a need for site-specific modification of immunoglobulins to establish homogenous immunoconjugates.
Researchers at the University of California, Davis have developed a unique method for site-specific ligation and conjugation of compounds to antibodies via direct binding of a ligand to the Fab arm. This method can be used to conjugate compounds to existing monoclonal and polyclonal antibodies, reducing production costs and shortening the preclinical-to-clinical translation times. The modification itself can be performed in very mild conditions, providing a viable method to create uniform antibody drug conjugates and bispecific antibodies. The method has been verified in vitro with human breast cancer cells and trastuzmab.
|United States Of America
Additional Patent Pending